References
- Akgun Z, Saglam S, Yucel S, Gural Z, Balik E, Cipe G, Yildiz S, Kilickap S, Okyar A, Kaytan-Saglam E. 2014. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. Cancer Chemother Pharmacol. 74(4):751–756. doi:https://doi.org/10.1007/s00280-014-2558-x
- Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. 2017. Systems chronotherapeutics. Pharmacol Rev. 69(2):161–199. doi:https://doi.org/10.1124/pr.116.013441
- Barnes JW, Tischkau SA, Barnes JA, Mitchell JW, Burgoon PW, Hickok JR, Gillette MU. 2003. Requirement of mammalian timeless for Circadian rhythmicity. Science (80-). 302(5644):439–442. doi:https://doi.org/10.1126/science.1086593
- Bass J. 2012. Circadian topology of metabolism. Nature. 491(7424):348–356. doi:https://doi.org/10.1038/nature11704
- Bever SR, Dib P, Strehle LD, Haynes BE, Hilvert AM, McKim D, Godbout JP, Sheridan JF, Obrietan K, Pyter LM. 2017. Tumors and tumor resection alter circadian rhythms. Brain Behav Immun. 66:e19. doi:https://doi.org/10.1016/j.bbi.2017.07.077
- Brady JJ, Chuang CH, Greenside PG, Rogers ZN, Murray CW, Caswell DR, Hartmann U, Connolly AJ, Sweet-Cordero EA, Kundaje A, et al. 2016. An Arntl2-driven secretome enables lung adenocarcinoma metastatic self-sufficiency. Cancer Cell. 29(5):697–710. doi:https://doi.org/10.1016/j.ccell.2016.03.003
- Buhr ED, Takahashi JS. 2013. Molecular components of the mammalian circadian clock. Handb Exp Pharmacol. 217:3–27. doi:https://doi.org/10.1007/978-3-642-25950-0_1
- Cadenas C, Van De Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenführer J, Oster H, Hengstler JG. 2014. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 13(20):3282–3291. doi:https://doi.org/10.4161/15384101.2014.954454
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. 2014. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 14(8):535–546. doi:https://doi.org/10.1038/nrc3775
- Da Cunha Santos G, Shepherd FA, Tsao MS. 2011. EGFR mutations and lung cancer. Annu Rev Pathol Mech Dis. 6(1):49–69. doi:https://doi.org/10.1146/annurev-pathol-011110-130206
- Dallmann R, Okyar A, Lévi F. 2016. Dosing-time makes the poison: Circadian regulation and pharmacotherapy. Trends Mol Med. 22(5):430–445. doi:https://doi.org/10.1016/j.molmed.2016.03.004
- Dulong S, Ballesta A, Okyar A, Levi F. 2015. Identification of circadian determinants of cancer chronotherapy through in vitro chronopharmacology and mathematical modeling. Mol Cancer Ther. 14(9):2154–2164. doi:https://doi.org/10.1158/1535-7163.MCT-15-0129
- Eckel-Mahan K, Sassone-Corsi P 2013. Epigenetic regulation of the molecular clockwork. Prog Mol Biol Transl Sci. 119:29–50. doi:https://doi.org/10.1016/B978-0-12-396971-2.00002-6
- El-Athman R, Genov NN, Mazuch J, Zhang K, Yu Y, Fuhr L, Abreu M, Li Y, Wallach T, Kramer A, et al. 2017. The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity.Taghert P, editor. PLOS Biol. 15(12):e2002940. doi:https://doi.org/10.1371/journal.pbio.2002940
- Evans JA, Davidson AJ 2013. Health consequences of circadian disruption in humans and animal models. Prog Mol Biol Transl Sci. 119:283–323. doi:https://doi.org/10.1016/B978-0-12-396971-2.00010-5
- Filipski E, Amat S, Lemaigre G, Vincenti M, Breillout F, Lévi FA. 1999. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J Pharmacol Exp Ther. 289(1):231–235.
- Filipski E, Innominato PF, Wu M, Li X-M, Iacobelli S, Xian L-J, Lévi F. 2005. Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst. 97(7):7. doi:https://doi.org/10.1093/jnci/dji083
- Focan C. 1995. Circadian rhythms and cancer chemotherapy. Pharmacol Ther. 67(1):1–52. doi:https://doi.org/10.1016/0163-7258(95)00009-6
- Focan C. 2002. Chronobiological concepts underlying the chronotherapy of human lung cancer. Chronobiol Int. 19(1):253–273. doi:https://doi.org/10.1081/CBI-120002601
- Fu L, Kettner NM. 2013. The circadian clock in cancer development and therapy. In: Prog Mol Biol Transl Sci. 119:221–282. doi:https://doi.org/10.1016/B978-0-12-396971-2.00009-9
- Fu L, Lee CC. 2003. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 3(5):350–361. doi:https://doi.org/10.1038/nrc1072
- Gauger MA, Sancar A. 2005. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 65(15):6828–6834. doi:https://doi.org/10.1158/0008-5472.CAN-05-1119
- Gérard C, Goldbeter A. 2012. Entrainment of the mammalian cell cycle by the circadian clock: modeling two coupled cellular rhythms.Crampin EJ, editor. PLoS Comput Biol. 8(5):e1002516. doi:https://doi.org/10.1371/journal.pcbi.1002516
- Gong J, Li Y, Jie LC, Xiang Y, Li C, Ye Y, Zhang Z, Hawke DH, Park PK, Diao L, et al. 2017. A pan-cancer analysis of the expression and clinical relevance of small nucleolar rnas in human cancer. Cell Rep. 21(7):1968–1981. doi:https://doi.org/10.1016/j.celrep.2017.10.070
- Grutsch JF, Ferrans C, Wood PA, Du-Quiton J, Quiton DFT, Reynolds JL, Ansell CM, Oh EY, Daehler MA, Levin RD, et al. 2011. The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer. 11(1):193. doi:https://doi.org/10.1186/1471-2407-11-193
- Guerrero-Vargas NN, Navarro-Espíndola R, Guzmán-Ruíz MA, Basualdo MC, Espitia-Bautista E, López-Bago A, Lascurain R, Córdoba-Manilla C, Buijs RM, Escobar C. 2017. Circadian disruption promotes tumor growth by anabolic host metabolism; experimental evidence in a rat model. BMC Cancer. 17(1):625. doi:https://doi.org/10.1186/s12885-017-3636-3
- Han L, Diao L, Yu S, Xu X, Jie L, Zhang R, Yang Y, Werner HMJ, Eterovic AK, Yuan Y, et al. 2015. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell. 28(4):515–528. doi:https://doi.org/10.1016/j.ccell.2015.08.013
- Hastings MH, Reddy AB, Maywood ES. 2003. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 4(8):649–661. doi:https://doi.org/10.1038/nrn1177
- He B, Nohara K, Park N, Park YS, Guillory B, Zhao Z, Garcia JM, Koike N, Lee CC, Takahashi JS, et al. 2016. The small molecule nobiletin targets the molecular oscillator to enhance Circadian rhythms and protect against metabolic syndrome. Cell Metab. 23(4):610–621. doi:https://doi.org/10.1016/j.cmet.2016.03.007
- Herbert J. 1994. The Suprachiasmatic Nucleus. The Minds Clock. J Anat. 184(Pt 2):431.
- Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, Zhu Y. 2010. Phenotypic effects of the circadian gene cryptochrome 2 on cancer-related pathways. BMC Cancer. 10(1):110. doi:https://doi.org/10.1186/1471-2407-10-110
- Hoffman AE, Zheng T, Ba Y, Zhu Y. 2008. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res. 6(9):1461–1468. doi:https://doi.org/10.1158/1541-7786.MCR-07-2094
- Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y. 2009. Clock-cancer connection in non-Hodgkin’s lymphoma: a genetic association study and pathway analysis of the Circadian gene cryptochrome 2. Cancer Res. 69(8):3605–3613. doi:https://doi.org/10.1158/0008-5472.CAN-08-4572
- Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. 2013. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 143(5 SUPPL)143(5 Suppl):e278S–e313S. doi:https://doi.org/10.1378/chest.12-2359
- Hsu CM, Lin SF, Lu CT, Lin PM, Yang MY. 2012. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumor Biol. 33(1):149–155. doi:https://doi.org/10.1007/s13277-011-0258-2
- Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F. 2006. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 97(7):589–596. doi:https://doi.org/10.1111/j.1349-7006.2006.00225.x
- Huber AL, Papp SJ, Chan AB, Henriksson E, Jordan SD, Kriebs A, Nguyen M, Wallace M, Li Z, Metallo CM, et al. 2016. CRY2 and FBXL3 cooperatively degrade c-MYC. Mol Cell. 64(4):774–789. doi:https://doi.org/10.1016/j.molcel.2016.10.012
- Hurley JM, Loros JJ, Dunlap JC. 2016. Circadian oscillators: around the transcription–translation feedback loop and on to output. Trends Biochem Sci. 41(10):834–846. doi:https://doi.org/10.1016/j.tibs.2016.07.009
- Hutchinson BD, Shroff GS, Truong MT, Ko JP. 2019. Spectrum of Lung Adenocarcinoma. Semin Ultrasound CT MRI. 40(3):255–264. doi:https://doi.org/10.1053/j.sult.2018.11.009
- Innominato PF, Lévi FA, Bjarnason GA. 2010. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev. 62(9–10):979–1001. doi:https://doi.org/10.1016/j.addr.2010.06.002
- Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Lévi FA. 2014. The circadian timing system in clinical oncology. Ann Med. 46(4):191–207. doi:https://doi.org/10.3109/07853890.2014.916990
- Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Levi F. 2009. Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int. 26(6):1169–1188. doi:https://doi.org/10.3109/07420520903209942
- Karatsoreos IN, Silver R. 2007. Minireview: the neuroendocrinology of the suprachiasmatic nucleus as a conductor of body time in mammals. Endocrinology. 148(12):5640–5647. doi:https://doi.org/10.1210/en.2007-1083
- Kiessling S, Beaulieu-Laroche L, Blum ID, Landgraf D, Welsh DK, Storch KF, Labrecque N, Cermakian N. 2017. Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol. 15(1):13. doi:https://doi.org/10.1186/s12915-017-0349-7
- Ko CH, Takahashi JS. 2006. Molecular components of the mammalian circadian clock. Hum Mol Genet. 15(SUPPL.2):R271–R277. doi:https://doi.org/10.1093/hmg/ddl207
- Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, Takahashi JS. 2012. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science (80-). 338(6105):349–354. doi:https://doi.org/10.1126/science.1226339
- Kondratov R. 2014. Circadian clock and cancer therapy: an unexpected journey. Ann Med. 46(4):189–190. doi:https://doi.org/10.3109/07853890.2014.920213
- Kuo TT, Ladurner AG. 2019. Exploiting the Circadian Clock for improved cancer therapy: perspective from a cell biologist. Front Genet. 10:1210. doi:https://doi.org/10.3389/fgene.2019.01210
- Lamia KA. 2017. Ticking time bombs: connections between circadian clocks and cancer. F1000Research. 6:1910. doi:https://doi.org/10.12688/f1000research.11770.1
- Le Minh N, Damiola F, Tronche F, Schütz G, Schibler U. 2001. Glucocorticoid hormones inhibit food-induced phase-shifting of peripheral circadian oscillators. EMBO J. 20(24):7128–7136. doi:https://doi.org/10.1093/emboj/20.24.7128
- Lee C, Etchegaray JP, Cagampang FRA, Loudon ASI, Reppert SM. 2001. Posttranslational mechanisms regulate the mammalian circadian clock. Cell. 107(7):855–867. doi:https://doi.org/10.1016/S0092-8674(01)00610-9
- Lee JH, Sancar A. 2011. Regulation of apoptosis by the circadian clock through NF-κB signaling. Proc Natl Acad Sci U S A. 108(29):12036–12041. doi:https://doi.org/10.1073/pnas.1108125108
- Lemjabbar-Alaoui H, Hassan OUI, Yang YW, Buchanan P. 2015. Lung cancer: biology and treatment options. Biochim Biophys Acta - Rev Cancer. 1856(2):189–210. doi:https://doi.org/10.1016/j.bbcan.2015.08.002
- Lévi F. 1997. Chronopharmacology of anticancer agents. In: Redfern PH, Lemmer B, eds. Handbook of experimental pharmacology. Springer: Berlin, Heidelberg. Vol. 125, p. 299–331. doi:https://doi.org/10.1007/978-3-662-09355-9_11
- Lévi F 2006. The circadian timing system, a coordinator of life processes. Implications for the rhythmic delivery of cancer therapeutics. Conf Proc IEEE Eng Med Biol Soc. Suppl:6736–6739. doi:https://doi.org/10.1109/IEMBS.2006.260934
- Lévi F, Dugué PA, Innominato P, Karaboué A, Dispersyn G, Parganiha A, Giacchetti S, Moreau T, Focan C, Waterhouse J, et al. 2014. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 31(8):891–900. doi:https://doi.org/10.3109/07420528.2014.924523
- Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. 2010. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 50(1):377–421. doi:https://doi.org/10.1146/annurev.pharmtox.48.113006.094626
- Levi F, Schibler U 2006. Circadian rhythms: mechanisms and therapeutic implications.
- Levin RD, Daehler MA, Grutsch JF, Quiton J, Lis CG, Peterson C, Gupta D, Watson K, Layer D, Huff-Adams S, et al. 2005. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 93(11):1202–1208. doi:https://doi.org/10.1038/sj.bjc.6602859
- Li J, Chen R, Ji M, Zou SL, Zhu LN. 2015. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 76(3):651–655. doi:https://doi.org/10.1007/s00280-015-2804-x
- Lin JD, Liu C, Li S. 2008. Integration of energy metabolism and the mammalian clock. Cell Cycle. 7(4):453–457. doi:https://doi.org/10.4161/cc.7.4.5442
- Logan RW, Zhang C, Murugan S, O’Connell S, Levitt D, Rosenwasser AM, Sarkar DK. 2012. Chronic shift-lag alters the Circadian clock of NK cells and promotes lung cancer growth in rats. J Immunol. 188(6):2583–2591. doi:https://doi.org/10.4049/jimmunol.1102715
- Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y. 2015. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumor Biol. 36(5):3533–3539. doi:https://doi.org/10.1007/s13277-014-2989-3
- Masri S, Papagiannakopoulos T, Kinouchi K, Liu Y, Cervantes M, Baldi P, Jacks T, Sassone-Corsi P. 2016. Lung adenocarcinoma distally rewires hepatic Circadian homeostasis. Cell. 165(4):896–909. doi:https://doi.org/10.1016/j.cell.2016.04.039
- Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. 2003. Control mechanism of the circadian clock for timing of cell division in vivo. Science (80-). 302(5643):255–259. doi:https://doi.org/10.1126/science.1086271
- Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, Andriulli A, Piepoli A. 2012. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol. 138(3):501–511. doi:https://doi.org/10.1007/s00432-011-1126-6
- Mormont MC, Levi F. 2003. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 97(1):155–169. doi:https://doi.org/10.1002/cncr.11040
- Mormont M-C, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset J-L, Touitou Y, Lévi F. 2000. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 6(8):3038–3045.
- Mullenders J, Fabius AWM, Madiredjo M, Bernards R, Beijersbergen RL. 2009. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.Ng IOL, editor. PLoS One. 4(3):e4798. doi:https://doi.org/10.1371/journal.pone.0004798
- Ohdo S, Inoue K, Yukawa E, Higuchi S, Nakano S, Ogawa N. 1997. Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics. Jpn J Pharmacol. 75(3):283–290. doi:https://doi.org/10.1254/jjp.75.283
- Padmanabhan K, Robles MS, Westerling T, Weitz CJ. 2012. Feedback regulation of transcriptional termination by the mammalian circadian clock PERIOD complex. Science (80-). 337(6094):599–602. doi:https://doi.org/10.1126/science.1221592
- Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. 2016. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 24(2):324–331. doi:https://doi.org/10.1016/j.cmet.2016.07.001
- Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. 2008. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 26(21):3552–3559. doi:https://doi.org/10.1200/JCO.2007.13.9030
- Qiu M, Bing CY, Jin S, Fang XF, He XX, Fan XZ, Li YS. 2019. Research on circadian clock genes in non-small-cell lung carcinoma. Chronobiol Int. 36(6):739–750. doi:https://doi.org/10.1080/07420528.2018.1509080
- Relógio A, Thomas P, Medina-Pérez P, Reischl S, Bervoets S, Gloc E, Riemer P, Mang-Fatehi S, Maier B, Schäfer R, et al. 2014. Ras-Mediated Deregulation of the Circadian Clock in Cancer.Levi F, editor. PLoS Genet. 10(5):e1004338. doi:https://doi.org/10.1371/journal.pgen.1004338
- Relógio A, Westermark PO, Wallach T, Schellenberg K, Kramer A, Herzel H. 2011. Tuning the mammalian circadian clock: robust synergy of two loops.Jensen LJ, editor. PLoS Comput Biol. 7(12):e1002309. doi:https://doi.org/10.1371/journal.pcbi.1002309
- Reppert SM, Weaver DR. 2002. Coordination of circadian timing in mammals. Nature. 418(6901):935–941. doi:https://doi.org/10.1038/nature00965
- Sahar S, Sassone-Corsi P. 2009. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 9(12):886–896. doi:https://doi.org/10.1038/nrc2747
- Sancar A, Lindsey-Boltz LA, Kang TH, Reardon JT, Lee JH, Ozturk N. 2010. Circadian clock control of the cellular response to DNA damage. FEBS Lett. 584(12):2618–2625. doi:https://doi.org/10.1016/j.febslet.2010.03.017
- Sancar G, Brunner M. 2014. Circadian clocks and energy metabolism. Cell Mol Life Sci. 71(14):2667–2680. doi:https://doi.org/10.1007/s00018-014-1574-7
- Schernhammer ES, Feskanich D, Liang G, Han J. 2013. Rotating night-shift work and lung cancer risk among female nurses in the United States. Am J Epidemiol. 178(9):1434–1441. doi:https://doi.org/10.1093/aje/kwt155
- Seok WS, Stockwell BR. 2008. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol. 9(6):R92. doi:https://doi.org/10.1186/gb-2008-9-6-r92
- Sephton SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhabhar FS, Spiegel D, Salmon P. 2013. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun. 30(SUPPL):S163–S170. doi:https://doi.org/10.1016/j.bbi.2012.07.019
- Shilts J, Chen G, Hughey JJ. 2018. Evidence for widespread dysregulation of circadian clock progression in human cancer. PeerJ. 2018(1):e4327. doi:https://doi.org/10.7717/peerj.4327
- Siegel RL, Miller KD, Fuchs HE, Jemal A. 2021. Cancer statistics, 2021. CA Cancer J Clin. 71(1):7–33. doi:https://doi.org/10.3322/caac.21654
- Stevens RG, Blask DE, Brainard GC, Hansen J, Lockley SW, Provencio I, Rea MS, Reinlib L 2007. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect. 115(9):1357–1362. doi:https://doi.org/10.1289/ehp.10200
- Takahashi JS, Hong HK, Ko CH, McDearmon EL. 2008. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 9(10):764–775. doi:https://doi.org/10.1038/nrg2430
- Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, François E, Bissery MC, Lévi F. 1998. Docetaxel Chronopharmacology in mice. Cancer Res. 58(17):3896–904.
- The Suprachiasmatic Nucleus. The mind’s clock. accessed 2021 Feb 23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1260009/
- Turek FW. 1994. Circadian rhythms. Recent Prog Horm Res. 49(1):43–90. doi:https://doi.org/10.1016/b978-0-12-571149-4.50007-6
- Ueda HR 2007. Systems biology of mammalian circadian clocks. Cold Spring Harb Symp Quant Biol. 72:365-80. doi:https://doi.org/10.1101/sqb.2007.72.047
- Ünsal-Kaçmaz K, Mullen TE, Kaufmann WK, Sancar A. 2005. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 25(8):3109–3116. doi:https://doi.org/10.1128/MCB.25.8.3109-3116.2005
- Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, Iino M, Hashimoto S. 2005. System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet. 37(2):187–192. doi:https://doi.org/10.1038/ng1504
- Vasu VT, Cross CE, Gohil K. 2009. Nr1d1, an important circadian pathway regulatory gene, is suppressed by cigarette smoke in murine lungs. Integr Cancer Ther. 8(4):321–328. doi:https://doi.org/10.1177/1534735409352027
- Wang Z, Wan C, Lay Y, Cornelissen G, Halberg F. 1995. Role of biological clocks in normal conditions, pathology, and in therapy. 2. Clinical chronoradiotherapy of lung cancer. Biofizika. 40(5):996–998.
- Welsh DK, Takahashi JS, Kay SA. 2010. Suprachiasmatic Nucleus: cell autonomy and network properties. Annu Rev Physiol. 72(1):551–577. doi:https://doi.org/10.1146/annurev-physiol-021909-135919
- Wood PA, Du-Quiton J, You S, Hrushesky WJM. 2006. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 5(8):2023–2033. doi:https://doi.org/10.1158/1535-7163.MCT-06-0177
- Xiang R, Cui Y, Wang Y, Xie T, Yang X, Wang Z, Li J, Li Q. 2018a. Circadian clock gene Per2 downregulation in non-small cell lung cancer is associated with tumour progression and metastasis. Oncol Rep. 40(5):3040–3048. doi:https://doi.org/10.3892/or.2018.6704
- Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang Z, Mills T, Chen NY, Kim Y, Ozguc FM, et al. 2018b. Comprehensive characterization of alternative polyadenylation in human cancer. J Natl Cancer Inst. 110(4):379–389. doi:https://doi.org/10.1093/jnci/djx223
- Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C, et al. 2018. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst. 6(3):314–328.e2. doi:https://doi.org/10.1016/j.cels.2018.01.013
- Yoshida K, Sato M, Hase T, Elshazley M, Yamashita R, Usami N, Taniguchi T, Yokoi K, Nakamura S, Kondo M, et al. 2013. TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. Cancer Sci. 104(2):171–177. doi:https://doi.org/10.1111/cas.12068
- Yuan P, Li J, Zhou F, Huang Q, Zhang J, Guo X, Lyu Z, Zhang H, Xing J. 2017. NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A. Cell Death Dis. 8(3):e2704–e2704. doi:https://doi.org/10.1038/cddis.2017.131
- Zarogoulidis P, Darwiche K, Huang H, Spyratos D, Yarmus L, Li Q, Kakolyris S, Syrigos K, Zarogoulidis K. 2013. Time recall; future concept of chronomodulating chemotherapy for cancer. Curr Pharm Biotechnol. 14(6):632–642. doi:https://doi.org/10.2174/13892010113146660229
- Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH. 2014. Overexpression of the circadian clock gene bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 20(4):1042–1052. doi:https://doi.org/10.1158/1078-0432.CCR-13-0171
- Zeng Z-L, Wu M-W, Sun J, Sun Y-L, Cai Y-C, Huang Y-J, Xian L-J. 2010. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem. 148(3):319–326. doi:https://doi.org/10.1093/jb/mvq069
- Zhang L, Ptáček LJ, Fu YH 2013. Diversity of human clock genotypes and consequences. Prog Mol Biol Transl Sci. 119:51–81. doi:https://doi.org/10.1016/B978-0-12-396971-2.00003-8
- Zhu Y, Stevens RG, Hoffman AE, FitzGerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL. 2009. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 69(24):9315–9322. doi:https://doi.org/10.1158/0008-5472.CAN-09-0648